PharmaPoint: Seasonal Influenza Vaccines – Global Drug Forecast and Market Analysis to 2025

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection's rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

Today, available vaccines include the older egg-based, adjuvanted and non- adjuvanted inactivated vaccines, along with live-attenuated vaccines and newer, cell culture-based seasonal influenza vaccines. Within these four vaccine classes, continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. The anticipated launch of quadrivalent, cell culture-based VLP vaccines will have the potential to revolutionize the approaches used to protect against seasonal influenza infections. GlobalData expects the global seasonal influenza vaccines market - which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) - to grow moderately during the next decade at a CAGR of 3.3%, reaching total sales of $4.3 billion by 2025.

Scope

Overview of seasonal influenza, including epidemiology, etiology, pathophysiology, as well current routine seasonal influenza vaccine recommendations of all 7MM covered.

Top-line seasonal influenza vaccine market revenue from 2015–2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the seasonal influenza vaccine market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

Analysis of the current and future market competition in the global seasonal influenza vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the seasonal influenza vaccine marketplace.

What will be the effect of recent and upcoming changes in national immunization schedules?

How will the upcoming first-in-class Virus-Like Particle (VLP) vaccine be received in the different markets?

What research and development (R&D) strategies will companies leverage to compete in the future seasonal influenza vaccine marketplace?

Which patient population(s) are most likely to be targeted by seasonal influenza vaccines?

Companies mentioned

GlaxoSmithKline

Sanofi Pasteur

CSL Limited (Seqirus)

AstraZeneca (MedImmune)

Protein Sciences Corporation

Mitsubishi Tanabe Pharma

Novavax

GlaxoSmithKline

Sanofi Pasteur

CSL Limited (Seqirus)

AstraZeneca (MedImmune)

Protein Sciences Corporation

Mitsubishi Tanabe Pharma

Novavax

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.1.3Symptoms and ...

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.1.3Symptoms and Prognosis

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1Historical Perspective of Vaccination Coverage

4.3.2Laboratory Confirmed Influenza Cases

4.3.3Hospitalization Due to Influenza

4.3.4Influenza Averted Cases

4.4Forecast Methodology

4.4.1Sources Used Tables

4.4.2Forecast Assumptions and Methods

4.4.3Sources Not Used

4.5Epidemiological Forecast for Seasonal Influenza (2015–2025)

4.5.1Seasonal Influenza Vaccination

4.5.2Seasonal Influenza Vaccination Rates

4.5.3Diagnosed Outpatient Influenza-Like Illness Incident Cases

4.5.4Lab Confirmed Incident Cases of Seasonal Influenza

4.5.5Influenza-Related Hospitalized Incident Cases

4.5.6Cases Averted by Seasonal Influenza Vaccinations

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of Analysis

4.6.3Strengths of Analysis

5Disease Management

5.1Seasonal Influenza Immunization Policy

5.1.1Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines

5.2US

5.2.1Influenza Immunization Recommendations and Policies

5.2.2Clinical Practice

5.3France

5.3.1Influenza Immunization Recommendations and Policies

5.3.2Clinical Practice

5.4Germany

5.4.1Influenza Immunization Recommendations and Policies

5.4.2Clinical Practice

5.5Italy

5.5.1Influenza Immunization Recommendations and Policies

5.5.2Clinical Practice

5.6Spain

5.6.1Influenza Immunization Recommendations and Policies

5.6.2Clinical Practice

5.7UK

5.7.1Influenza Immunization Recommendations and Policies

5.7.2Clinical Practice

5.8Japan

5.8.1Influenza Immunization Recommendations and Policies

5.8.2Clinical Practice

6Competitive Assessment

6.1Overview

6.2Product Profiles – Major Brands, Inactivated Vaccines

6.2.1Fluzone Quadrivalent

6.2.2Fluzone High-Dose

6.2.3Fluzone Intradermal

6.2.4Vaxigrip

6.2.5Fluarix Tetra

6.2.6Fluvirin

6.2.7Afluria

6.2.8Agrippal

6.3Product Profiles – Major Brands, Inactivated Vaccines (Adjuvanted)

6.3.1Fluad

6.4Product Profiles – Major Brands, Live-Attenuated Vaccines

6.4.1FluMist Quadrivalent

6.5Product Profiles – Major Brands, Cell Cultured Vaccines

6.5.1Flublok

6.5.2Flucelvax

6.6Other Seasonal Influenza Vaccines

6.6.1Influvac

6.6.2Minor Brands

7Unmet Needs and Opportunity Analysis

7.1Overview

7.2Higher Level of Public Awareness and Positive Perception of Influenza Vaccines

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Immunization Policies Targeting Children and Adolescents

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Enhanced Vaccine Efficacy in High-Risk Groups

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Vaccines Leveraging Innovative and Efficient Manufacturing Technologies

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

7.6Improving the Cost-Effectiveness of Influenza Vaccines

7.6.1Unmet Need

7.6.2Gap Analysis

7.6.3Opportunity

7.7Vaccines with Broader Influenza Strain Coverage

7.7.1Unmet Need

7.7.2Gap Analysis

7.7.3Opportunity

7.8Improved Vaccine Safety Profile

7.8.1Unmet Need

7.8.2Gap Analysis

7.8.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Promising Vaccines in Clinical Development

8.2.1Seasonal Influenza VLP Vaccine

8.2.2VN-100

8.2.3Quadrivalent Seasonal Influenza VLP Vaccine

8.3Promising Vaccines in Early-Stage Development

8.3.1FLU-v

8.3.2M-001

8.3.3TAK-850

8.3.4VAX-2012Q

8.4Other Vaccines in Development Outside the 7MM

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles – Major Players

9.3.1Sanofi

9.3.2CSL Limited (Seqirus)

9.3.3GlaxoSmithKline

9.3.4AstraZeneca (MedImmune)

9.3.5Protein Sciences Corporation

9.3.6Mitsubishi Tanabe Pharma

9.3.7Novavax

9.4Other Companies

9.4.1Mylan

9.4.2Daiichi Sankyo

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.3France

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Germany

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

10.5Italy

10.5.1Forecast

10.5.2Key Events

10.5.3Drivers and Barriers

10.6Spain

10.6.1Forecast

10.6.2Key Events

10.6.3Drivers and Barriers

10.7United Kingdom

10.7.1Forecast

10.7.2Key Events

10.7.3Drivers and Barriers

10.8Japan

10.8.1Forecast

10.8.2Key Events

10.8.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Vaccine Coverage

11.4.2Vaccines Included

11.4.3Key Launch Dates

11.4.4Influenza Vaccine Tender System Assumptions

11.4.5General Pricing Assumptions

11.4.6Individual Vaccine Assumptions

11.4.7Pricing of Pipeline Agents

11.5Primary Research – KOLs Interviewed for this Report

11.6Primary Research – Prescriber Survey

11.7About the Authors

11.7.1Analyst

11.7.2Therapy Area Director

11.7.3Epidemiologists

11.7.4Director of Epidemiology

11.7.5Global Director of Therapy Analysis and Epidemiology

11.8About GlobalData

11.9Disclaimer

List of Tables

Table 1: Notable Influenza Pandemics

Table 2: Influenza Symptoms

Table 3: Risk Factors and Comorbidities for Seasonal Influenza

Table 4: 7MM, Historical Perspective of Seasonal ...

Table 1: Notable Influenza Pandemics

Table 2: Influenza Symptoms

Table 3: Risk Factors and Comorbidities for Seasonal Influenza

Table 4: 7MM, Historical Perspective of Seasonal Influenza Vaccination Coverage

Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Total Population Vaccination Rates of Seasonal Influenza

Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Outpatient Seasonal ILI

Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Laboratory Confirmed Incident Cases of Seasonal Influenza

Table 8: 7MM, Sources of Epidemiological Data Used to Forecast Seasonal Influenza-Related Hospitalized Incident Cases

Table 9: 7MM, Sources of Epidemiological Data Used to Forecast Averted Cases of Seasonal Influenza

Table 10: 7MM, Sources Not Used in Epidemiological Analysis of Seasonal Influenza

Table 11: 7MM, People Receiving Seasonal Influenza Vaccination, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 12: 7MM, Age-Specific Distribution of People Receiving Seasonal Influenza Vaccination, Both Sexes, N (Row %), 2015

Table 13: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N (Row %), 2015

Table 14: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, Selected Years 2015–2025

Table 15: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015

Table 16: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 17: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N (Row %), 2015

Table 18: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N (Row %), 2015

Table 19: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 20: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N (Row %), 2015

Table 21: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N (Row %), 2015

Table 22: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 23: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N (Row %), 2015

Table 24: 7MM, Influenza Related Hospitalized Incident Cases, All Ages, N (Row %), 2015

Table 25: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 26: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N (Row %), 2015

Table 27: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016

Table 28: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016

Table 29: Country Profile – US

Table 30: Country Profile – France

Table 31: Country Profile – Germany

Table 32: Country Profile – Italy

Table 33: Country Profile – Spain

Table 34: Country Profile – UK

Table 35: Country Profile –Japan

Table 36: Leading Seasonal Influenza Vaccines, 2016

Table 37: Product Profile – Fluzone Quadrivalent

Table 38: Immunogenicity Profile of Fluzone Quadrivalent

Table 39: Local and Systemic AEs of Fluzone Quadrivalent

Table 40: Fluzone Quadrivalent SWOT Analysis, 2016

Table 41: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015–2025

Table 42: Product Profile – Fluzone High-Dose

Table 43: Immunogenicity of Fluzone High-Dose Compared with Fluzone

Table 44: Local and Systemic AEs of Fluzone High-Dose

Table 45: Fluzone High-Dose SWOT Analysis, 2016

Table 46: Global Sales Forecast ($m) for Fluzone High-Dose, 2015–2025

Table 47: Product Profile – Fluzone Intradermal

Table 48: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent

Table 49: Local andsystemic AEs of Fluzone Intradermal Quadrivalent

Table 50: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016

Table 51: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015–2025

Table 52: Product Profile – Vaxigrip

Table 53: Cumulative Incidence of Influenza Infection in Children

Table 54: Local and Systemic AEs of Vaxigrip

Table 55: Vaxigrip SWOT Analysis, 2016

Table 56: Global Sales Forecast ($m) for Vaxigrip, 2015–2025

Table 57: Product Profile – Fluarix Tetra

Table 58: Immunogenicity Profile of Fluarix Tetra

Table 59: Local and Systemic AEs of Fluarix Tetra

Table 60: Fluarix Tetra SWOT Analysis, 2016

Table 61: Global Sales Forecast ($m) for Fluarix Tetra, 2015–2025

Table 62: Product Profile – Fluvirin

Table 63: Immunogenicity of Fluvirin in Adults

Table 64: Local and Systemic AEs of Fluvirin

Table 65: Fluvirin SWOT Analysis, 2016

Table 66: Global Sales Forecast ($m) for Fluvirin, 2015–2025

Table 67: Product Profile – Afluria

Table 68: Immunogenicity of Afluria in Adults

Table 69: Local and Systemic AEs of Afluria

Table 70: Afluria SWOT Analysis, 2016

Table 71: Global Sales Forecast ($m) for Afluria, 2015–2025

Table 72: Product Profile – Agrippal

Table 73: Immunogenicity of Agrippal

Table 74: Local and Systemic AEs of Agrippal

Table 75: Agrippal SWOT Analysis, 2016

Table 76: Global Sales Forecast ($m) for Agrippal, 2015–2025

Table 77: Product Profile – Fluad

Table 78: Immunogenicity Comparison of Fluad Versus Agriflu

Table 79: Local and Systemic AEs of Fluad

Table 80: Fluad SWOT Analysis, 2016

Table 81: Global Sales Forecast ($m) for Fluad, 2015–2025

Table 82: Product Profile – FluMist Quadrivalent

Table 83: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent

Table 84: AEs of FluMist Quadrivalent

Table 85: FluMist Quadrivalent SWOT Analysis, 2016

Table 86: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015–2025

Table 87: Product Profile – Flublok

Table 88: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose

Table 89: Local and Systemic AEs of Flublok

Table 90: Flublok SWOT Analysis, 2016

Table 91: Global Sales Forecast ($m) for Flublok, 2015–2025

Table 92: Product Profile – Flucelvax

Table 93: Immunogenicity of Flucelvax

Table 94: Local and Systemic AEs of Flucelvax

Table 95:Flucelvax SWOT Analysis, 2016

Table 96: Global Sales Forecast ($m) for Flucelvax, 2015–2025

Table 97: Summary of Other Marketed Seasonal Influenza Vaccines, 2016

Table 98: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016

Table 99: Seasonal Influenza Vaccines – Late-Stage Pipeline, 2016

Table 100: Quadrivalent Versions of Marketed Vaccines

Table 101: Product Profile – Seasonal Influenza VLP Vaccine

Table 102: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 103: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015–2025

Table 104: Product Profile – VN-100

Table 105: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine

Table 106: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine

Table 107: VN-100 SWOT Analysis, 2016

Table 108: Global Sales Forecast ($m) for VN-100, 2015–2025

Table 109: Product Profile – Quadrivalent Seasonal Influenza VLP Vaccine

Table 110: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 111: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015–2025

Table 112: Promising Vaccines in Early-Stage Development, 2016

Table 113: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016

Table 114: Key Companies in the Seasonal Influenza Vaccines Market, 2016

Table 115: Sanofi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 116: CSL Limited’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 117: GSK’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 118: AstraZeneca’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 119: Protein Sciences Corporation’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 120: Mitsubishi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 121: Novavax’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 122: Global (7MM) Sales Forecasts ($m) for Seasonal Influenza Vaccines, 2015–2025

Table 123: Seasonal Influenza Vaccines Market – Drivers and Barriers, 7MM, 2015–2025

Table 124: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the US, 2015–2025

Table 125: Key Events Impacting Sales for Seasonal Influenza in the US, 2015?2025

Table 126: US Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 127: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 –2025

Table 128: Key Events Impacting Sales for Seasonal Influenza in France, 2015?2025

Table 129: France Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 130: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 –2025

Table 131: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015?2025

Table 132: Germany Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 133: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015–2025

Table 134: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015?2025

Table 135: Italy Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 136: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 –2025

Table 137: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015?2025

Table 138: Spain Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 139: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015–2025

Table 140: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015?2025

Table 141: UK Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 142: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015–2025

Table 143: Key Events Impacting Sales for Seasonal Influenza in Japan 2015?2025

Table 144: Japan Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 145: Key Launch Dates

Table 146: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Influenza Virus Structure

Figure 2: 7MM, Cases with Seasonal Influenza Vaccination, All Ages, Both Sexes, N, 2015–2025

Figure 3: 7MM, Age-Specific Cases with ...

Figure 1: Influenza Virus Structure

Figure 2: 7MM, Cases with Seasonal Influenza Vaccination, All Ages, Both Sexes, N, 2015–2025

Figure 3: 7MM, Age-Specific Cases with Seasonal Influenza Vaccination, Both Sexes, N, 2015

Figure 4: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N, 2015

Figure 5: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, 2015–2025

Figure 6: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015

Figure 7: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 8: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N, 2015

Figure 9: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N, 2015

Figure 10: 7MM, Age-Standardized Diagnosed Outpatient ILI Incidence, All Ages, Cases per 100,000 Population, 2015

Figure 11: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 12: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N, 2015

Figure 13: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N, 2015

Figure 14: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 15: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N, 2015

Figure 16: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, N, 2015

Figure 17: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 18: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N, 2015

Figure 19: Seasonal Influenza Vaccines – Phase II/Phase III Pipeline, 2016

Figure 20: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015–2025

Figure 21: Company Portfolio Gap Analysis in Seasonal Influenza Vaccines, 2015–2025

Figure 22: Global (7MM) Sales for Seasonal Influenza Vaccines by Country, 2015 and 2025

Figure 23: Sales of Seasonal Influenza Vaccines by Class in the US, 2015 and 2025

Figure 24: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025

Figure 25: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025

Figure 26: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025

Figure 27: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025

Figure 28: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025

Figure 29: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports